Smartee Denti-Technology Releases 2025 Year-in-Review: 100,000 GS Mandibular Repositioning Cases, Global Expansion, and Manufacturing Scale-Up

SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- Smartee Denti-Technology today released its 2025 annual review, detailing a pivotal year characterized by the worldwide clinical application of its proprietary mandibular repositioning technology, the inauguration of new European infrastructure, and a strategic partnership with the Straumann Group.

The 2025 review highlights Smartee's transition from rapid growth to sustained maturity, underscored by advancements in three key pillars: clinical efficacy, global supply chain capability, and professional education.

Clinical Milestone: Applicating Mandibular Repositioning at Scale

A central achievement of 2025 was the crossing of the 100,000-case threshold for the Smartee GS Mandibular Repositioning technology. This volume represents significant real-world evidence for the efficacy of using clear aligners to treat severe jaw discrepancies, specifically Class II and Class III malocclusions, via mandibular repositioning rather than traditional extraction or surgical mechanics.

Academic recognition of this approach accelerated throughout the year. The Journal of Aligner Orthodontics (JAO) published two separate papers on Smartee's protocols:

• Issue 2, 2025: A report by Dr. Xingxing Wang, Smartee Medical Director, on treatment of Class II malocclusion with sagittal-guidance twin block clear aligners (S8-SGTB).
• Issue 4, 2025: A research paper titled "Working Mechanism and Clinical Management of Mandibular Advancement Repositioning Technology in Treating Three-Depth Malocclusion in Adult Patients" by Prof. Gang Shen, Smartee GS Chief Scientist, and his orthodontic team, further documenting clinical outcomes.

Operational Expansion and New Partnership

In 2025, Smartee expanded its production capacity to meet growing international demand by launching a new 100,000-square-meter intelligent manufacturing campus.  The facility features fully automated production lines enhanced with additional modular capabilities and supports both internal product lines and external partners.

This production capability was validated in October through a strategic partnership with the Straumann Group. Under the agreement, Smartee will provide manufacturing support for Straumann's clear aligner brand, ClearCorrect, in selected EMEA and APAC markets, leveraging its advanced infrastructure to provide customized production solutions while ensuring product consistency.

R&D Breakthroughs: Sleep Appliance & AI Integration

In the fourth quarter of 2025, Smartee diversified its clinical portfolio with two major technological launches aimed at multidisciplinary care and workflow efficiency.

Smartee Sleep Aligners (Oct. 1): Smartee entered the sleep apnea device market with the launch of the Smartee Sleep Aligner series, designed to treat mild-to-moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS). The series features a patented digital twin-splint locking system for mandibular advancement and an ultra-thin 1mm profile which provides much more comfortable wearing experience than conventional appliances.

Clinical Impact: The device is engineered to expand the oropharyngeal airway by up to 23%. The launch introduced two variations: the SA for standalone sleep therapy, and the SA Plus, which combines airway management with simultaneous orthodontic tooth movement—positioning it as a pioneering dual-action solution.

Smartee Live 3D (Oct. 30): To enhance efficiency in digital treatment planning, Smartee introduced Live 3D, an AI-driven treatment planning tool. By leveraging deep learning algorithms, Live 3D generates initial 3D treatment designs in just 30 minutes. Coupled with Smartee LiveUpdate, this digital ecosystem allows clinicians to move from case upload, treatment plan revision to final approval in less than one hour, significantly accelerating the total production turnaround time.

Global Footprint: Localization in Europe

To support its growing partner base, Smartee established a dedicated UK subsidiary and inaugurated the European Orthodontic Clinical Support Center in Stoke-on-Trent. This center provides region-specific treatment planning and clinical support, ensuring that digital treatment plans align strictly with local medical standards and biomechanical preferences.

Educational Outreach: Bridging Global and Regional Markets

Smartee's commitment to academic exchange remained robust in 2025, with participation in 27 major international congresses (including IDS Cologne and SEDO Spain) and the organization of extensive proprietary training:

• Global Tours: The "Smartee GS" mandibular repositioning technology lecture series toured 17 cities worldwide—including Paris, Tokyo, and Rome—training over 11,000 professionals.
• China Market: Domestic training programs reached 14,330 participants. Notably, Smartee extended advanced orthodontic education beyond first-tier cities into emerging markets such as Weifang, Lanzhou, and Kunming, fostering ecosystem development in lower-tier regions.
• Pediatric Early Orthodontics Focus: Highlighting early intervention, Smartee hosted Pediatric Early Orthodontics and Orofacial Myofunctional Therapy summits in Singapore, Melbourne, and Disneyland® Paris, as well as the International Symposium on Myofunctional Therapy in Shanghai.

Concurrently, Smartee advanced its ESG commitments, implementing solar energy projects projected to reduce CO₂ emissions by 209 tons annually, alongside digital governance systems to enhance employee wellness.

About Smartee Denti-Technology
Founded in 2004, Smartee is a global leader in digital orthodontics and clear aligner manufacturing. With four R&D centers and four manufacturing bases across China and Spain, Smartee serves over 99,000 partner doctors in 57 countries. Its portfolio includes the Smartee GS (Mandibular Repositioning), Smartee GE, and Smartee Kinder/Teen series.

  

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Smartee Denti-Technology Releases 2025 Year-in-Review: 100,000 GS Mandibular Repositioning Cases, Global Expansion, and Manufacturing Scale-Up

Smartee Denti-Technology Releases 2025 Year-in-Review: 100,000 GS Mandibular Repositioning Cases, Global Expansion, and Manufacturing Scale-Up

Smartee Denti-Technology Releases 2025 Year-in-Review: 100,000 GS Mandibular Repositioning Cases, Global Expansion, and Manufacturing Scale-Up

Smartee Denti-Technology Releases 2025 Year-in-Review: 100,000 GS Mandibular Repositioning Cases, Global Expansion, and Manufacturing Scale-Up

Smartee Denti-Technology Releases 2025 Year-in-Review: 100,000 GS Mandibular Repositioning Cases, Global Expansion, and Manufacturing Scale-Up

SEOUL, South Korea, Jan. 20, 2026 /PRNewswire/ -- Digital healthcare startup 6Letters today announced the official launch of MOJO KING, an iOS application that enables non-invasive monitoring of testosterone-related physiological patterns using Apple Watch data.

MOJO KING leverages heart rate variability (HRV)—a standard biometric signal collected by Apple Watch—to analyze changes associated with male hormonal balance. Without requiring blood tests or external sensors, the app allows users to track hormone-related trends seamlessly in everyday life.

The current version of MOJO KING analyzes individual biometric signals in relation to age-group baselines and 24-hour circadian rhythms. Based on this analysis, users are classified into intuitive categories: "Teto Guy" when values are above the age-adjusted average, or "Egen Guy" when below. Results are presented in a user-friendly visual format and can be easily shared via social media platforms such as Instagram.

With a paid subscription, users can remove in-app advertisements and enable automatic, continuous measurements, allowing them to observe personalized hormone-related changes over time. This supports a shift from one-time readings to longitudinal, trend-based hormone monitoring tailored to individual lifestyles.

MOJO KING is built on a foundation of multiple patents and peer-reviewed scientific research. To further enhance accuracy and personalization, 6Letters is currently training machine-learning models using large-scale medical datasets from the UK Biobank, CDC, Physionet etc. Insights derived from this work will power the next generation of the company's hormone analytics platform.

Notably, MOJO KING goes beyond conventional smartwatch fitness use cases that focus primarily on heart rate and respiration during aerobic exercise. The app introduces a differentiated approach by analyzing pre- and post-changes associated with moderate-to-high-intensity resistance training, offering new insights into hormone-related responses to strength-focused workouts.

Looking ahead, 6Letters plans to expand MOJO KING with additional modes, including hormone-dependent hair loss management and growth-phase optimization. The company is also preparing to launch MOJO QUEEN, a complementary digital health application focused on female hormone analytics.

In parallel, 6Letters is currently conducting a pre-seed funding round at an approximate company valuation of USD 5 million. The company expects to complete AI training based on a huge medical data and plans to apply for FDA 510(k) clearance in the first half of 2026, followed by entry into the U.S. Remote Patient Monitoring (RPM) reimbursement market.

MOJO KING is designed to help users understand and manage hormone-related physiological signals in everyday life, said a representative of 6Letters. By combining scientific evidence, large-scale medical data, and wearable technology, 6Letters aims to build a globally scalable digital hormone health platform.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

6Letters Launches "MOJO KING," an Apple Watch-Based iOS App for Non-Invasive Testosterone Monitoring